Increasing the Share of Own Products in the Domestic Market
First written in FY2016. 21 of 28 entries say "Restated". Latest entry: 2026-07-28.
The whole theme swung hardest in 2024: 2 of 18 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「In addition, to strengthen our competitiveness in the domestic market, we will promote the development of new test items for latex reagents and work to expand the lung cancer test items available on the multiplex gene mutation detection system (MINtS), which uses next-generation sequencing.」
In addition to the previous policy of maintaining domestic sales and increasing market share, the company added the development of new latex reagent test items and expansion of MINtS lung cancer test items as specific measures. - FY2025-H1RestatedAnnual report
「Urinalysis reagents totaled ¥2,293 million, up 11.1% year on year, on strong sales of urine test strips in both domestic and overseas markets. Immunoserology reagents totaled ¥11,484 million, down 0.1%, as fecal occult blood testing reagents remained firm in Japan but declined overseas.」
Domestic sales of urinalysis reagents increased 11.1% year on year and sales of fecal occult blood testing reagents remained firm, while fecal occult blood testing reagents for overseas markets declined. The policy of maintaining domestic sales and increasing market share remains in place. - FY2024-Q3AdvancedAnnual report
「Urinalysis reagents totaled ¥3,222 million, up 3.9% year on year, as Japan's hospital and health-check markets recovered to pre-pandemic levels. Immunoserology reagents totaled ¥16,935 million, up 5.6%, as fecal occult blood testing reagents recovered to pre-pandemic levels domestically and overseas sales increased substantially.」
Japan's hospital and health-check markets and fecal occult blood testing reagents recovered to pre-pandemic levels. Urinalysis reagents increased 3.9% year on year, while immunoserology reagents increased 5.6%. - FY2024-Q2AdvancedAnnual report
「Urinalysis reagents totaled ¥2,064 million, up 2.4% year on year, as Japan's hospital and health-check markets recovered to pre-pandemic levels. Immunoserology reagents totaled ¥11,500 million, up 9.4%, as fecal occult blood testing reagents recovered to pre-pandemic levels domestically and overseas sales increased substantially.」
Japan's hospital and health-check markets and fecal occult blood testing reagents recovered to pre-pandemic levels. Urinalysis reagents increased 2.4% year on year, while immunoserology reagents increased 9.4%. - FY2023-Q2RestatedAnnual report
「Sales of immunoserology reagents increased in Japan, but sales of fecal occult blood testing reagents for overseas markets declined, resulting in revenue of ¥10,507 million, down 1.2% year on year.」
Although domestic sales of immunoserology reagents increased, the segment as a whole declined 1.2% year on year because of the decrease in fecal occult blood testing reagents for overseas markets. The policy of maintaining and expanding domestic sales remains in place. - FY2023-Q1RestatedAnnual report
「During the first quarter of the fiscal year, revenue increased as various health-check and screening programs resumed and outpatient numbers began to recover following the decline in COVID-19 cases. Sales grew domestically, mainly for the core fecal occult blood testing and urinalysis reagents, resulting in revenue of ¥11,097 million, up 5.5% year on year.」
The document describes growth in sales of the company's core domestic products, fecal occult blood testing reagents and urinalysis reagents, but does not provide a figure for its domestic market share. - FY2022AdvancedAnnual report
「The restart of various health-check and screening programs and the recovery trend in outpatient numbers drove strong growth in immunoserology reagents, including fecal occult blood testing reagents. In addition, the spread of COVID-19 in the fourth quarter drove strong growth in COVID-19 detection reagents, leading the increase in sales.」
Against the backdrop of the restart of health-check and screening programs and the recovery in outpatient numbers, immunoserology reagents, including those sold domestically, grew, while COVID-19 detection reagents also drove sales growth. - FY2022-Q3RestatedAnnual report
「The four priority measures are establishing the foundations for greater management efficiency, promoting global expansion, maintaining and increasing domestic sales and market share, and strengthening R&D capabilities.」
We continue to maintain and increase domestic sales and market share as one of the priority measures under the EIKEN ROAD MAP 2019. - FY2022-Q2RestatedAnnual report
「The four priority measures are establishing the foundations for greater management efficiency, promoting global expansion, maintaining and increasing domestic sales and market share, and strengthening R&D capabilities.」
We continue to maintain and increase domestic sales and market share as one of the priority measures under the EIKEN ROAD MAP 2019. - FY2022-Q1RestatedAnnual report
「The four priority measures are establishing the foundations for greater management efficiency, promoting global expansion, maintaining and increasing domestic sales and market share, and strengthening R&D capabilities.」
We continue to maintain and increase domestic sales and market share as one of the priority measures under the EIKEN ROAD MAP 2019. - FY2020RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. For urinalysis reagents and analyzers, we promoted bundled sales of the US-3500 fully automated urine analyzer and urine sediment equipment and worked to secure new adopters.」
The Group continues to pursue measures to maintain domestic sales and increase market share through the installation of PLEDIA, expansion of new adopters, awareness activities for colorectal cancer screening, and bundled sales of the US-3500 and urine sediment equipment. - FY2020-Q2RestatedAnnual report
「Maintaining domestic sales and increasing market share」
The Group continues to pursue maintaining domestic sales and increasing market share as one of the priority measures based on EIKEN ROAD MAP2019. - FY2020-Q1RestatedAnnual report
「Maintaining domestic sales and increasing market share」
Maintaining domestic sales and increasing market share continues as one of the priority measures based on EIKEN ROAD MAP2019. - FY2019RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. For urinalysis reagents and analyzers, we promoted bundled sales of the US-3500 fully automated urine analyzer and urine sediment equipment and worked to secure new adopters.」
The Group continues to pursue its policy of increasing domestic market share, citing bundled sales of the US-3500 and urine sediment equipment, in addition to PLEDIA and other existing products, as a means of achieving it. - FY2019-Q3RestatedAnnual report
「Domestic sales of urinalysis reagents increased, reaching ¥2.208 billion, up 4.6% year on year. Although sales of AIA-related immunoserological testing reagents introduced and sold by TOSOH CORPORATION declined, sales of fecal occult blood testing reagents overseas increased substantially and domestic sales remained firm, reaching ¥15.578 billion, up 5.8% year on year.」
Domestic sales of urinalysis reagents increased 4.6% year on year, while domestic sales of fecal occult blood testing reagents remained firm. The Group continues to pursue its policy of expanding core products in Japan. - FY2019-Q2RestatedAnnual report
「Domestic sales of urinalysis reagents increased, reaching ¥1.422 billion, up 3.6% year on year. Although sales of AIA-related immunoserological testing reagents introduced and sold by TOSOH CORPORATION declined, sales of fecal occult blood testing reagents overseas increased substantially and domestic sales remained firm, reaching ¥10.289 billion, up 5.0% year on year.」
Domestic sales of urinalysis reagents increased 3.6% year on year, while domestic sales of fecal occult blood testing reagents remained firm. The Group continues to pursue its policy of expanding core products in Japan. - FY2019-Q1RestatedAnnual report
「Reagents for immunoserological testing, including AIA-related reagents introduced and sold by TOSOH CORPORATION, declined slightly. However, sales of fecal occult blood testing reagents overseas increased substantially, while domestic sales remained firm, resulting in sales of ¥5.186 billion, up 5.3% year on year.」
For fecal occult blood testing reagents, the Group reported strong growth in overseas sales and firm domestic sales, and continues to pursue its policy of expanding core products in Japan. - FY2018RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2018-Q3RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2018-Q2RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2018-Q1RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2017RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2017-Q3RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2017-Q2RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening. We also promoted sales of the ImmunoCatch rapid test kits based on the immunochromatographic method, focusing on ImmunoCatch-Legionella and ImmunoCatch-Streptococcus pneumoniae.」
The Group continues to pursue measures to increase domestic market share through the installation of PLEDIA, expansion of new adopters, screening awareness activities and promotion of ImmunoCatch series sales. - FY2017-Q1RestatedAnnual report
「For our fecal occult blood testing reagents, a core product, we promoted the installation of the OC-SENSOR PLEDIA fecal occult blood analyzer and focused on expanding the number of new adopters, while conducting awareness activities to increase participation in colorectal cancer screening.」
The goal of increasing domestic market share was reiterated, with the installation of PLEDIA, expansion of new adopters and screening awareness activities identified as the means of achieving it. - FY2016First statedAnnual report
「①Increasing the market share of our products in Japan」
It is explicitly identified as one of the priority issues in the management strategy.